Avidity Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
RNA Nasdaq 8731 https://www.aviditybiosciences.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Avidity Biosciences Inc

Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001) - Oct 3rd, 2024 11:00 am
Is Avidity Biosciences, Inc. (RNA) the Best Performing Long Term Stock in 2024? - Sep 29th, 2024 10:27 am
Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024? - Sep 26th, 2024 11:34 pm
Avidity Biosciences to Participate in Upcoming Investor Conference - Sep 25th, 2024 1:00 pm
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 23rd, 2024 8:05 pm
Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month - Sep 5th, 2024 1:00 pm
Avidity Biosciences to Participate in Upcoming Investor Conferences - Aug 28th, 2024 1:00 pm
Avidity, Kymera raise fresh funds; Walgreens partners with BARDA - Aug 20th, 2024 11:44 am
Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Aug 19th, 2024 1:00 pm
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock - Aug 15th, 2024 12:29 am
Avidity Biosciences Announces Proposed Public Offering of Common Stock - Aug 13th, 2024 8:01 pm
Company News for Aug 13, 2024 - Aug 13th, 2024 1:39 pm
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates - Aug 9th, 2024 9:20 pm
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics - Aug 9th, 2024 8:17 pm
Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights - Aug 9th, 2024 8:05 pm
Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44™ Trial - Aug 9th, 2024 11:00 am
Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer - Aug 5th, 2024 1:00 pm
3 Stocks Doing Even Better Than Superstar Super Micro (SMCI) - Jul 24th, 2024 10:41 am
3 Russell 2000 Growth Stocks That Could Be Worth the Risk - Jul 23rd, 2024 11:00 am
Avidity’s FSHD drug del-brax shows promise in Phase I/II trial - Jul 3rd, 2024 10:53 am